BioPharmSignal logoBioPharmSignal

Biotech News

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Innoviva (INVA)InnovivaCompany update

Agreement expands access to XACDURO ® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals) The rate of carbapenem resistant

Related news

INVAInnoviva2026-08-11 20:05 EST

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

INVAInnoviva2026-09-02 12:00 EST

Innoviva to Participate in Upcoming Investor Conferences

FULCFulcrum Therapeutics2026-08-17 11:00 EST

Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies

BCRXBioCryst Pharmaceuticals2026-05-04 11:00 EST

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

FULCFulcrum Therapeutics2026-03-19 12:00 EST

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

GSKGSK plc2026-01-20 12:00 EST

GSK enters agreement to acquire RAPT Therapeutics

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

GSKGSK plc2026-06-17 16:00 EST

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

PMVPPMV Pharmaceuticals2026-03-06 13:00 EST

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

View all latest news

Innoviva

Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies. Respiratory Royalties The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support...

Recent company news

INVAInnoviva2026-09-02 12:00 EST

Innoviva to Participate in Upcoming Investor Conferences

INVAInnoviva2026-08-11 20:05 EST

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-06-18 12:00 EST

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

INVAInnoviva2026-06-16 12:00 EST

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Stock data

Close
21.04 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States